(NASDAQ: RVMD) Revolution Medicines's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.22%.
Revolution Medicines's earnings in 2026 is -$1,768,285,000.On average, 25 Wall Street analysts forecast RVMD's earnings for 2026 to be -$2,133,676,174, with the lowest RVMD earnings forecast at -$2,594,113,667, and the highest RVMD earnings forecast at -$1,755,415,263. On average, 25 Wall Street analysts forecast RVMD's earnings for 2027 to be -$1,476,392,114, with the lowest RVMD earnings forecast at -$1,963,964,598, and the highest RVMD earnings forecast at -$432,102,219.
In 2028, RVMD is forecast to generate -$685,383,564 in earnings, with the lowest earnings forecast at -$2,140,406,337 and the highest earnings forecast at $2,216,774,403.